LifeCell Corporation

LifeCell Corporation has been granted 125 US utility patents between 2015 and 2025, placing LifeCell Corporation at rank #3,041 across all assignees tracked by PlainPatent. This portfolio spans 34 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.6 claims per patent with primary concentration in A61L (METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES;). As a US Corporation, LifeCell Corporation is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 48.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 50 grants, compared with 75 in the 2015–2019 window — a -33% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. LifeCell Corporation's 17.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 34 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark LifeCell Corporation against peers pursuing similar technology classes.